Potential liver toxicity in diabetics using Rezulin (troglitazone)

    There's a growing concern about potential liver toxicity in diabetics using Rezulin (troglitazone).

    Rezulin has been given to over half a million patients since it came out early last year.

    But now there are over 150 reports of possible liver dysfunction...resulting in one liver transplant and several deaths.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

  • 12 issues every year — what you need to know and do, right now
  • Quick, practical reference charts and tools
  • Comprehensive CE library to meet license renewal and state requirements
  • Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
  • Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote